Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals

Abstract Background Due to promising preclinical studies and clinical case reports, Tb-161 labeled radiopharmaceuticals for targeted radionuclide therapy (TRT) have gained interest. Unlike Lu-177, Tb-161 not only emits β− particles, but also Auger and conversion electrons, which may improve the curr...

詳細記述

書誌詳細

主要な著者:	Carolline M. Ntihabose, Maryana Handula, Amber Piet, Savanne Beekman, Louise van Dalen, Negin Eskandari, Asude Aydogan, Debra Stuurman, Corrina de Ridder, Mark Konijnenberg, Yann Seimbille, Erik de Blois
フォーマット:	Artigo
言語:	Inglês
出版事項:	SpringerOpen 2025-10-01
シリーズ:	EJNMMI Radiopharmacy and Chemistry
主題:	Terbium-161 Lutetium-177 Targeted radionuclide therapy (TRT) Radiopharmaceuticals Active pharmaceutical ingredient (API)
オンライン･アクセス:	https://doi.org/10.1186/s41181-025-00390-3
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!